Eitan Moshe Akirav

Title: Eitan Moshe Akirav: Innovator in Diabetes Biomarkers

Introduction

Eitan Moshe Akirav is a notable inventor based in Plainview, NY (US). He has made significant contributions to the field of diabetes research, particularly in the analysis of biomarkers related to beta-cell loss. With a total of 5 patents, his work is paving the way for advancements in diabetes diagnostics.

Latest Patents

One of his latest patents is titled "System, method and kit for analysis of circulating differentially methylated DNA as a biomarker of beta-cell loss." This invention addresses the challenge of detecting beta-cell loss in Type 1 diabetes, which often goes unnoticed until hyperglycemia develops. The patent describes a method using methylation-sensitive quantitative real-time PCR (qRTPCR) to analyze circulating free beta-cell specific DNA, including insulin and amylin gene DNA. By determining a gene demethylation index, this method can effectively identify beta-cell death. Another significant patent is the "Method for using probe-based PCR detection to measure the levels of circulating demethylated beta-cell derived DNA as a measure of beta-cell loss in diabetes." This method allows for the sensitive detection of beta-cell DNA released upon cell death, providing a valuable bioassay for monitoring diabetes progression and therapy selection.

Career Highlights

Eitan has worked with reputable institutions such as NYU Winthrop Hospital and Winthrop University Hospital. His experience in these organizations has contributed to his expertise in diabetes research and biomarker analysis.

Collaborations

He has collaborated with notable professionals in the field, including Kevan C. Herold, enhancing the impact of his research through shared knowledge and expertise.

Conclusion

Eitan Moshe Akirav's innovative work in diabetes biomarkers is crucial for improving the detection and management of diabetes. His patents reflect a commitment to advancing medical science and enhancing patient care.